Updates

Explore Medicines360’s latest news and resources

Press Releases

Medicines360 Awarded “Clinical Trial Result of the Year” at 2019 CARE Awards

SAN FRANCISCO – Medicines360, a nonprofit, global women’s health pharmaceutical company with a mission of expanding access to quality medicines, was awarded the Clinical Trial Result of the Year at the 2019 Clinical and Research Excellence (CARE) Awards. The CARE Awards celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing […]

Read More >
Press Releases

Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.

Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented new six-year data from Medicines360’s ongoing […]

Read More >
Press Releases

Power to Decide and Medicines360 Announce Partnership to Expand Access to Contraception

WASHINGTON, D.C. – Today, millions of women in need of contraception struggle with access to this basic part of women’s health care. To help women access this needed service, Power to Decide and Medicines360, a mission-driven nonprofit women’s health pharmaceutical, will partner to help expand access to contraception for all women. This partnership aims especially to help […]

Read More >
Press Releases

Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years

Data from ACCESS IUS, the largest ongoing Phase 3 clinical trial in the U.S. of an intrauterine system evaluating pregnancy prevention, also reports bleeding profile over five years in diverse women SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA is highly efficacious in preventing pregnancy over five […]

Read More >
Press Releases

FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years

DUBLIN and SAN FRANCISCO – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for […]

Read More >
Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >

FEATURED UPDATES

News

International Women’s Day at Direct Relief International

SANTA BARBARA INDEPENDENT – Direct Relief’s Kirchmaier Volunteer Center was standing room only Friday morning, March 8, as more than 150 people gathered in honor of International Women’s Day to celebrate achievements and acknowledge remaining hurdles, including the lack of global access to affordable maternal health care. This year’s theme was “balance for better — […]

Read More >
Press Releases

Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg

Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]

Read More >
News

Medicines360 Expands Access To Contraception In Africa

FORBES – Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.

Read More >